Myriad Genetics, Inc. MYGN
Set alert
At close · Oct 30
After hours · Oct 30, 7:51 PM ET
- YTD
- +3.25%
- 1 year
- -20.13%
- Open
- 6.51
- Prev close
- 6.67
- Mkt cap
- 607.38M
- Vol
- 1.50M
- Avg vol
- 2.64M
- EPS
- -1.18
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 6.29
- High
- 6.66
- Forward P/E
- 71.53
- Beta
- 1.89
- Short ratio
- 4.83
- Inst. own
- 103.89%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 13.32
- 200-d avg
- 21.11
- 1y target
- 19.41
2Y chart
Events in this range
- Nov 7, 2024Earnings: 0.06; estimate 0.02; surprise 200%
- Jan 16, 2025Rating: Stephens & Co. · Equal-Weight → Equal-Weight
- Jan 28, 2025Rating: Goldman Sachs · Buy → Buy
- Jan 30, 2025Rating: Piper Sandler · Neutral → Neutral
- Feb 12, 2025Rating: Craig-Hallum · — → Buy
- Feb 24, 2025Earnings: 0.03; estimate 0.03; surprise 0%
- Feb 25, 2025Rating: UBS · Neutral → Neutral
- Feb 25, 2025Rating: Raymond James · Outperform → Outperform
Signals (94)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Overbought | Oct 20, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 17, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| RSI: Oversold | Jul 31, 2026 | 3 months ago |
| SMA: Bearish | Jul 24, 2026 | 3 months ago |
| SMA: Bullish | Jul 23, 2026 | 3 months ago |
| SMA: Bearish | Jul 22, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 20, 2026 | 3 months ago |
| RSI: Overbought | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jul 9, 2026 | 3 months ago |
| SMA: Bullish | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| RSI: Overbought | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 18, 2026 | 4 months ago |
| SMA: Bearish | Jun 12, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | Jun 4, 2026 | 4 months ago |
| MACD: Buy Signal | May 27, 2026 | 5 months ago |
| RSI: Oversold | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | May 6, 2026 | 5 months ago |
| MACD: Buy Signal | May 5, 2026 | 5 months ago |
| SMA: Bullish | May 1, 2026 | 6 months ago |
| SMA: Bearish | Apr 29, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 27, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 25, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 24, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 23, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 20, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 25, 2026 | 8 months ago |
| RSI: Oversold | Feb 5, 2026 | 8 months ago |
| RSI: Oversold | Jan 20, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 15, 2026 | 9 months ago |
| SMA: Bearish | Jan 13, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
| SMA: Bullish | Jan 6, 2026 | 9 months ago |
| SMA: Bearish | Dec 23, 2025 | 10 months ago |
| SMA: Bullish | Dec 22, 2025 | 10 months ago |
| SMA: Bearish | Dec 19, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 15, 2025 | 10 months ago |
| SMA: Bearish | Dec 1, 2025 | 11 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bullish | Nov 21, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 21, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| SMA: Bullish | Oct 15, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 25, 2025 | 1 year ago |
| RSI: Overbought | Sep 19, 2025 | 1 year ago |
| RSI: Overbought | Sep 11, 2025 | 1 year ago |
| RSI: Overbought | Sep 2, 2025 | 1 year ago |
| RSI: Overbought | Aug 8, 2025 | 1 year ago |
| SMA: Bullish | Aug 6, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 6, 2025 | 1 year ago |
| RSI: Oversold | Jul 31, 2025 | 1 year ago |
| SMA: Bearish | Jul 17, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| MACD: Buy Signal | May 22, 2025 | 1 year ago |
| RSI: Oversold | May 21, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| RSI: Oversold | May 7, 2025 | 1 year ago |
| RSI: Oversold | Apr 29, 2025 | 1 year ago |
| RSI: Oversold | Apr 17, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 11, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 28, 2025 | 1 year ago |
| RSI: Oversold | Mar 28, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 20, 2025 | 1 year ago |
| RSI: Oversold | Mar 7, 2025 | 1 year ago |
| RSI: Oversold | Feb 28, 2025 | 1 year ago |
| SMA: Bearish | Feb 25, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| SMA: Bullish | Feb 13, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 30, 2025 | 1 year ago |
| RSI: Oversold | Jan 22, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 17, 2025 | 1 year ago |
| RSI: Oversold | Jan 16, 2025 | 1 year ago |
| RSI: Oversold | Jan 2, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 30, 2024 | 1 year ago |
Key statistics
- Market cap
- 979.65M
- Enterprise value
- 1.05B
- Trailing P/E
- 0.00
- Forward P/E
- 71.53
- PEG ratio
- 0.00
- Price / sales
- 1.17
- Price / book
- 1.40
- EPS (TTM)
- -1.41
- Beta
- 1.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -15.20%
- Revenue (TTM)
- 837.60M
- Revenue growth
- 7.10%
- Free cash flow
- 11.76M
- Total cash
- 102.40M
- Total debt
- 140.30M
- Return on equity
- -17.15%
- Shares outstanding
- 91.30M
- Short % of float
- 8.31%
- 50-day average
- 13.32
- 200-day average
- 21.11
Analyst view
Consensus: buy
- Target (low)
- 11.00
- Target (mean)
- 19.41
- Target (high)
- 29.00
- Strong buy4
- Buy4
- Hold5
- Sell1
- Strong sell2
Next earnings
Consensus EPS estimate -0.06447.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2025 | Dec 1, 2024 | 0.03 | 0.03 | 0.00 | 0.00% |
| Nov 7, 2024 | Sep 1, 2024 | 0.02 | 0.06 | +0.04 | +200.00% |
| Aug 6, 2024 | Jun 1, 2024 | — | 0.05 | +0.06 | +600.00% |
| Feb 27, 2024 | Dec 1, 2023 | 0.02 | 0.04 | +0.02 | +100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 25, 2025 | Raymond James | reit | Outperform | Outperform |
| Feb 25, 2025 | UBS | main | Neutral | Neutral |
| Feb 12, 2025 | Craig-Hallum | init | — | Buy |
| Jan 30, 2025 | Piper Sandler | main | Neutral | Neutral |
| Jan 28, 2025 | Goldman Sachs | main | Buy | Buy |
| Jan 16, 2025 | Stephens & Co. | reit | Equal-Weight | Equal-Weight |
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- myriad.com
News
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
- Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp
- Nasdaq Rises Over 100 Points; 3M Earnings Top Views
- Hasbro Posts Upbeat Q3 Earnings, Joins Myriad Genetics, Equifax And Other Big Stocks Moving Higher On Tuesday
- Myriad Genetics To Sell Its Prenatal Health Testing Business, Including Prequel, Foresight, SneakPeek And FirstGene Tests, To Labcorp For $210M In Cash Plus Inventory Value
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
- Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
- TD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $4.5
Your note
Sign in to keep a note on MYGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANCONA MARGARET | Officer | Sale | Aug 20, 2024 | 79,366 |
| DAVIS MARK STEVEN | Director | Stock Award(Grant) | Dec 9, 2024 | 22,816 |
| DIAZ PAUL J | Chief Executive Officer | Sale | Oct 10, 2024 | 962,378 |
| DREISMANN HEINRICH | Director | Sale | Sep 8, 2024 | 121,648 |
| FOX JENNIFER LYNNE | Officer | Stock Award(Grant) | Sep 2, 2024 | 61,771 |
| KUMAR RASHMI | Director | Sale | Aug 18, 2024 | 77,392 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.47% | 15,907,593 | 170.69M | Dec 30, 2024 |
| Vanguard Group Inc | 11.63% | 10,591,043 | 113.64M | Dec 30, 2024 |
| Wellington Management Group, LLP | 6.60% | 6,004,598 | 64.43M | Dec 30, 2024 |
| State Street Corporation | 6.07% | 5,525,705 | 59.29M | Dec 30, 2024 |
| Millennium Management Llc | 4.77% | 4,345,196 | 46.62M | Dec 30, 2024 |
| Glenview Capital Management, Llc | 4.57% | 4,157,324 | 44.61M | Dec 30, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 6.47% | 5,889,365 | 63.19M | Dec 30, 2024 |
| Vanguard Explorer Fund, Inc. | 3.51% | 3,193,902 | 34.27M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.97% | 2,701,054 | 28.98M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.66% | 2,417,661 | 25.94M | Dec 30, 2024 |
| Vanguard Small-Cap Index Fund | 2.37% | 2,157,138 | 23.15M | Sep 29, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 2.08% | 1,892,409 | 20.31M | Dec 30, 2024 |